Announcements Trials
Browse Landscape

Phase

Phase 3 8Phase 2 6Phase 1/2 5Phase 1 5

Status

Active not recruiting 3Recruiting 1Completed 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5CNS 1

Conditions

Carcinoma, Renal Cell 5Kidney Neoplasms 4Neoplasm Metastasis 2Glioblastoma 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × belzutifan × Clear all
NCT04846920 2026-05-22

MK-6482-018

Merck Sharp & Dohme LLC

Phase 1 Completed
29 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT06234605 2026-01-15

A Study of HC-7366 in Combination With Belzutifan (WELIREGâ„¢) in Patients With Renal Cell Carcinoma

HiberCell, Inc.

Phase 1 Recruiting
80 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT05030506 2025-12-18

MK-6482-010

Merck Sharp & Dohme LLC

Phase 1 Active not recruiting
45 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02974738 2025-07-10

MK-6482-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting
120 enrolled
CNSGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Kidney Neoplasms, Neoplasm Metastasis

NCT02293980 2024-06-17

MK-3795-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting
110 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡